[
    [
        {
            "time": "",
            "original_text": "医药生物行业: 注射剂一致性评价来临, 好处高质量龙头公司",
            "features": {
                "keywords": [
                    "医药生物",
                    "注射剂",
                    "一致性评价",
                    "高质量",
                    "龙头公司"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业: 注射剂一致性评价来临, 好处高质量龙头公司",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医药行业2018年投资策略：正本清源柳暗花明",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "2018年",
                    "正本清源"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2018年投资策略：正本清源柳暗花明",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：首批一致性评价品种出炉把握18年主线投资机会",
            "features": {
                "keywords": [
                    "医药行业",
                    "一致性评价",
                    "首批品种",
                    "投资机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：首批一致性评价品种出炉把握18年主线投资机会",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01",
            "original_text": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向 - 增持 - 0101",
            "features": {
                "keywords": [
                    "医药生物",
                    "政策落地",
                    "创新药",
                    "高品质仿制药",
                    "医疗服务"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向 - 增持 - 0101",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        }
    ]
]